iProov Achieves Record-breaking Growth as Demand for Genuine Presence Assurance™ Soars
iProov, world leader in secure biometric authentication technology, today announced record-breaking growth in the first half of 2021.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210728006091/en/
iProov's Genuine Presence Assurance™ technology verifies that an online user is the right person, a real person, authenticating right now. (Photo: Business Wire)
From January to June 2021, iProov saw a 15x increase in the number of people verified using its technology versus the same time period last year. Its flagship Genuine Presence Assurance technology solidified its global market leadership, with verifications growing at a consistent rate of 25% per month worldwide.
This has been driven by demand from organizations needing to verify the identity of online users to prevent fraud. iProov’s patented technology assures the genuine presence of an online user to ensure they are the right person, a real person, and authenticating right now.
iProov has been profitable in 2021, while at the same time growing its worldwide team by 25% to 85 staff. In April, the company welcomed cybersecurity veteran Paul King who joined iProov’s advisory board following 27 years at Cisco, most recently as Chief Security Officer. iProov has also been awarded numerous prestigious awards, including Best Biometric Solution at the 2021 Cyber Security Global Excellence Awards.
In what has been a tumultuous year across the globe, iProov’s technology has provided safe and secure digital identity verification for a growing range of vital services. Since the start of 2021, iProov has added major customers and partners to its portfolio spanning government, health, travel, financial services and ID providers.
In February iProov announced it had been selected by the Australian government to provide the liveness solution for myGovID. Millions of Australians will be able to strengthen their digital identity using a simple face scan on their mobiles, providing access to a range of government services, including online tax.
iProov’s existing service to NHS Digital in the UK became even more crucial this year. Since 2020, iProov has enabled users in England to create an NHS login remotely and securely. A user scans their identity document, such as a valid passport or driver’s license, and then completes a brief iProov face verification to confirm their identity, giving them secure access to the services of the NHS App. Since May 2021, this has included the COVID vaccination status service.
In January 2021, iProov announced a collaboration with its partner, Mvine, to trial private COVID status certificates. The solution enables an individual to register a test result or vaccination status and then securely share that status without disclosing their identity, using either paper or a smartphone. The trials, which took place in care and education settings, were backed by investment from Innovate UK and showcased how biometric verification could greatly simplify the checking of COVID status credentials while enhancing user privacy.
The iProov partner program grew by a third in the first six months of the year, from sectors including identity, health, travel and cryptocurrency. In April, Jumio, the leading provider of AI-powered end-to-end identity verification and eKYC solutions, announced that it had selected iProov technology to deliver high conversion rates, fast onboarding, a natural user experience and small SDK size to its customers.
Andrew Bud, iProov Founder and CEO, commented: “In the first half of 2021, iProov has secured users’ identities online and protected major organizations from fraud on a vast scale across the globe. The dramatic acceleration in the digital identity market, caused by the pandemic, has demonstrated our market leadership based on our unrivaled usability, inclusiveness and resilient security, and the extraordinary scalability of our platform. I am continually impressed by the remarkable work of the iProov team in successfully rising to the many challenges created by such transformative growth.”
The highlights from 2021 so far include: -
● iProov Takes Home Gold in Three Cybersecurity Excellence Awards: Government, Financial Services, and Identity Proofing & Corroboration - https://www.iproov.com/blog/cyber-security-awards-government-finance
● iProov wins Best Biometric Solution at 2021 Cyber Security Global Excellence Awards - https://www.iproov.com/blog/best-biometric-solution-cyber-security-2021
● iProov Named Winner of Coveted Global InfoSec Award During RSA Conference - https://www.iproov.com/press/iproov-winner-of-global-infosec-award-during-rsa-conference-2021
Customers and partners
● Australian Taxation Office extends national digital identity program with face verification technology from iProov - https://www.iproov.com/press/australian-taxation-office-national-digital-identity-program-face-verification-technology
● Jumio adds iProov’s award winning liveness detection to its KYC platform - https://www.iproov.com/press/jumio-adds-iproov-award-winning-liveness-detection-to-its-kyx-platform
● iProov selected by itsme to support global expansion - https://www.iproov.com/press/iproov-face-verification-selected-by-itsme-to-support-global-expansion
● COVID-19 certificate solution from iProov and Mvine moves into trial phase - https://www.iproov.com/press/uk-covid19-passport-moves-into-trial-phase
Senior team hires
● Cybersecurity veteran Paul King joins iProov’s Advisory Board - https://www.iproov.com/press/cyber-security-veteran-joins-iproov-advisory-board
Founded in 2012, iProov is the world leader in online facial biometric authentication, working with governments, financial institutions and other enterprises to securely verify customer identity. Used for effortless onboarding and authentication, customers include the U.S. Department of Homeland Security, the UK Home Office, the UK National Health Service (NHS), the Australian Taxation Office, GovTech Singapore, Rabobank, ING and others. iProov’s technologies include Liveness Assurance and Genuine Presence Assurance, which ensures that an online customer is the right person, a real person, and is authenticating right now. This protects against spoof attacks from photos, videos, masks and digital injection attacks that use deepfakes and other synthetic media. Supported by capital from private equity firm JRJ Group, iProov has grown a global footprint with offices in the UK, US and Singapore. iProov was recognized as a Gartner Cool Vendor 2020 in Identity Access Management & Fraud Detection and as the 5th fastest growing technology company in the UK in the Deloitte 2020 UK Technology Fast 50. For more information, please see www.iproov.com or follow us on LinkedIn or Twitter.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Boehringer Ingelheim Acquires Abexxa Biologics to Further Expand its Research Efforts in Cancer Immunology and Novel Immunotherapeutic Approaches21.9.2021 15:00:00 EEST | Press release
Boehringer Ingelheim today announced the acquisition of Abexxa Biologics Inc., a biopharmaceutical company taking a new approach in the fields of immuno-oncology and oncology research to develop the next generation of precision medicines designed to revolutionize cancer treatments. The acquisition will allow Boehringer Ingelheim to access Abexxa’s expertise in targeting cancer-specific proteins that are located inside the cell, rather than those expressed on the cell membrane. This enlarges the pool of potential cancer antigen targets. In particular, Abexxa’s technology could lead to the development of cancer immunotherapies that are effective in a broader range of patients and cancer types. “The acquisition of Abexxa bolsters our commitment to tumor-antigen discovery and new ways of targeting intracellular antigens. Their cutting-edge know-how and technologies for antigen discovery and novel antibody generation strongly complement the current approaches we have been applying successfu
CreatorIQ Expands Its Leadership Position With Acquisition of #1 Influencer Marketing Analytics Platform Tribe Dynamics21.9.2021 15:00:00 EEST | Press release
Influencer marketing platform, CreatorIQ — the most trusted partner advancing the creator economy for brands like AB InBev, Disney, Sephora, and Unilever — today announced the acquisition of the #1 influencer marketing analytics platform, Tribe Dynamics. The deal brings together Tribe Dynamics’ advanced analytics and benchmarking solutions — the industry standard for beauty and fashion brands like Estee Lauder, Fashion Nova, and LVMH — with the ability to make those insights actionable through CreatorIQ’s Creator Intelligence Cloud. The combined company will extend CreatorIQ’s leadership position as the largest influencer marketing SaaS platform in terms of revenue, growth, data authority, and global expansion with over 450 customers, 250 employees, and $90 million in funding. The companies provide an end-to-end solution for marketers to find, activate, manage and measure their creator relationships. As influencer marketing continues to grow in size, scope, and maturity, brands need in
Trialbee and Castor Partner to Democratize Access and Simplify Enrollment to Clinical Trials Globally21.9.2021 14:58:00 EEST | Press release
Trialbee, the leading enrollment performance company, and Castor, a leading provider of decentralized and hybrid clinical trial solutions, today announced a strategic partnership to accelerate patient enrollment, optimize patient engagement, and reduce site burden for clinical trials globally. Castor and Trialbee’s logical integration allows sponsors to meet enrollment timelines with continuous access to all their study data. Together, the fast-growing companies will expedite patient recruitment and streamline clinical trials through advanced data science and streamlined workflows for patient enrollment, data collection, and engagement. The partnership will diversify patient participation and improve equitable health outcomes for global decentralized and hybrid clinical programs. “We are excited to partner with Trialbee to improve patient engagement, as well as optimize patient diversity and study inclusivity with real-time insights around patient demographics across all recruitment ch
Trialbee and Castor Partner to Democratize Access and Simplify Enrollment to Clinical Trials Globally21.9.2021 14:58:00 EEST | Press release
Trialbee, the leading enrollment performance company, and Castor, a leading provider of decentralized and hybrid clinical trial solutions, today announced a strategic partnership to accelerate patient enrollment, optimize patient engagement, and reduce site burden for clinical trials globally. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210921005005/en/ Castor and Trialbee’s logical integration allows sponsors to meet enrollment timelines with continuous access to all their study data. Together, the fast-growing companies will expedite patient recruitment and streamline clinical trials through advanced data science and streamlined workflows for patient enrollment, data collection, and engagement. The partnership will diversify patient participation and improve equitable health outcomes for global decentralized and hybrid clinical programs. “We are excited to partner with Trialbee to improve patient engagement, as well as
Theramex launches Bijuva® / Bijuve® (estradiol and progesterone), the first and only body-identical combined hormone therapy treatment for post-menopausal women*21.9.2021 14:45:00 EEST | Press release
PRESCRIBING INFORMATION IS AVAILABLE AT THE END OF THIS RELEASE FOR MEDICAL BUSINESS / HEALTHCARE INDUSTRY TRADE MEDIA ONLY Theramex has today launched Bijuva® / Bijuve® (1mg estradiol / 100mg progesterone) across Europe and the UK. Bijuva®, (known as Bijuve® in the UK), is the first, and only, body-identical hormone therapy treatment (HRT) for estrogen deficiency symptoms in post-menopausal women with intact uterus and at least 12 months since last menses, which combines estradiol and progesterone in a single daily oral capsule.1,2 Unlike synthetic hormone products, the estradiol and progesterone found in Bijuva® / Bijuve® are chemically and biologically identical to the hormones naturally circulating in the woman’s body.3 Real-world evidence, recognised by NICE and the British Menopause Society, suggests that use of body‑identical hormones is associated with lower risks compared to synthetic versions. 4,5 In particular, the evidence base demonstrates that body-identical hormones have
Hologic Releases Results of Inaugural Global Women’s Health Index – First Study Representing the Health of 2.5 Billion Women and Girls21.9.2021 14:00:00 EEST | Press release
Hologic, Inc. (Nasdaq: HOLX), a global leader in women's health, today shared the findings from its inaugural Hologic Global Women’s Health Index, the world’s most comprehensive, globally comparative survey about women’s health. Developed in partnership with leading analytics and advice firm Gallup, the Hologic Global Women’s Health Index is an unprecedented, in-depth examination of critical markers for women’s health, by country and territory, and over time. Its findings are based on the experiences of more than 60,000 women and girls from 116 countries and territories, captured in more than 140 languages. Conducted as part of the Gallup World Poll, which began in 2005, the Hologic Global Women’s Health Index represents the feelings and actions of approximately 2.5 billion women and girls. Based on responses from the 120,000 total individuals surveyed, women’s health needs are not being met globally. The global score was 54 out of 100 on the Index, and no one country or territory scor
CBRE GLOBAL INVESTORS JULKAISEE EUROPEAN RESIDENTIAL IMPACT FUNDIN NELJÄN SIJOITTAJAN TEKEMÄLLÄ 465 MILJOONAN EURON PÄÄOMASITOUMUKSELLA21.9.2021 13:52:00 EEST | Tiedote
Tämä on markkinointiviesti. Tutustu CBRE European Residential Impact Fund S.C.A. SICAV-SIFin perustamiskirjaan ennen lopullisten sijoituspäätösten tekemistä. Tämän julkaisun kautta ei tehdä tarjousta yhdysvaltalaisille sijoittajille. Tämä julkaisu ei muodosta tarjousta myydä tai ostaa CBRE European Residential Impact Fund S.C.A. SICAV-SIFin osakkeita tai mitään muuta tuotetta, eivätkä yhdysvaltalaiset sijoittajat voi käyttää sitä tai tukeutua siihen tehdessään sijoituspäätöksiä. Kaikki tarjoukset tehdään vain luottamuksellisen perustamiskirjan ja siihen liittyvän tilaussopimuksen kautta, jotka toimitetaan vain päteville sijoittajille. Tämä lehdistötiedote sisältää multimediaa. Katso koko julkaisu täällä: https://www.businesswire.com/news/home/20210921005579/fi/ Paul Oremus, CBRE European Residential Impact Fundin rahastonhoitaja (Photo: Business Wire) CBRE Global Investors, joka on yksi maailman johtavia kiinteän omaisuuden hoitoyhtiöitä, ilmoittaa tänään CBRE European Residential Impa
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.Visit our pressroom